Treating chronic neurodisorders

Depressive Disorders: A Worrying Landscape

A huge public health issue and a huge, growing market

Depressive disorder

Urgent Needs for a better understanding of the disease and for innovation

20% to 40% patients are partial or non responders;
there is a 3-4 week delay before treatments start bringing benefits;
there are systematic, serious side effects (“serotonin syndrom”, mania/hypomania, bleeding, nausea, …);
50% patients discontinue treatment within 6 months because of side effects;
10% patients commit suicide!

they regulate monoamines neurotransmission (SSRIs, SNRIs).

We believe MAPREG is on the verge to bring a cutting-edge new drug to patients, a drug that is safer and faster than any other drug, based on a completely new mechanism of action, not involving monoamines.

The DEPSTER project, designed and piloted by MAPREG, made the awaited first original proof of concept to relieve depressive situation in relevant animal models.
Now Phase 2 clinical trial is about to be launched.

MAP4343 fills the gaps

A competitive innovative program granted 6th by EUROSTARS

In 3 different animal models of depressive disorder, MP4343*:

*MAP4343 was systematically compared to PROZAC, and proves better in all outcomes.

Aging Brain

Brain inherently ages and becomes slower, subject to failure of memory with correlative loss of self-confidence and desire to act. MAP4343 pharmacological profile allows to propose it as a safe drug to help people fight their cognitive impairments as well as mood disorders.

CHU Bicêtre, Batiment Pincus, 80 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France.